Neok Bio Inc.

据药明康德（603259）消息，截至2025年11月26日，2025年11月全球生物医药领域完成114起融资活动，累计融资总额超过36亿美元，其中22家创新药公司单笔融资额突破5000万美元。11月3日，AAVantgarde Bio完成1.41亿美元B轮融资，资金用于推进基因增补疗法临床项目，包括治疗Stargardt病的AAVB-039和治疗Usher综合征继发性视网膜色素变性的AAVB-081；首席执行官为Natalia Misciattelli博士。11月4日，NEOK Bio完成7500万美元A轮融资，专注于抗体偶联药物研发，计划2026年初提交靶向ROR1/B7-H3和EGFR/MUC1的候选药物IND；首席执行官为Mayank Gandhi博士。同日，Azalea Therapeutics完成8200万美元种子轮及A轮融资，推进基因编辑疗法EDV技术平台开发体内细胞工程；首席执行官为Jenny Hamilton博士。11月5日，Evommune通过IPO融资1.725亿美元，正在开发针对慢性炎症的口服小分子拮抗剂和融合蛋白疗法；首席执行官为Luis Pe a。11月18日，Solve Therapeutics完成1.2亿美元融资，资金用于加速ADC药物和CloakLink平台开发；首席执行官为David Johnson。11月20日，瑞普晨创完成5亿元A+轮融资，聚焦干细胞疗法用于糖尿病治疗；联合创始人兼董事长为丁列明博士。11月21日，拓济医药完成6000万美元Pre-A+轮融资，专注于双特异性抗体偶联药物研发；创始人兼首席执行官为陈兆远博士。

Eli Lilly is returning to South Korea for another deal. Lilly will pay $40 million upfront and up to $2.56 billion in biobucks to ABL Bio for access to the Seoul-based biotech’s so-called “Grabody” platform. Lilly will also purchase ABL shares in an equity investment worth about KRW 22 billion (approximately $15 million). ABL already has partnerships with Sanofi, NovaBridge Biosciences , Compass Therapeutics and others. Its Lilly partnership is almost identical in size to its neuro tie-up with GSK in April. The new duo didn’t disclose which therapeutic areas or specific modalities they plan to pursue. Like many other pharma companies, the world’s most valuable drugmaker frequently taps smaller biotechs for platform innovation. ABL’s platform centers on bispecifics, which have become a hotbed for biopharma dealmaking. The platform can apply to immune modulators, T cell engagers and various modalities that break through the blood-brain barrier. Earlier this month, the biotech also spun out a suite of ADC assets to California-based NEOK Bio . “We believe Grabody has already established a strong foothold, and we intend to build on this momentum by broadening its indications into therapeutic areas with high unmet medical needs, including obesity and muscle diseases,” ABL chief executive Sang Hoon Lee said in a press release. ABL’s pipeline includes multiple experimental cancer medicines and a Parkinson’s treatment candidate . Lilly also went to Korea earlier this year for a hearing loss-focused partnership with Rznomics. That RNA editing collaboration could potentially be a $1.3 billion boon to Rznomics , if all goes according to plan.

ABL Bio has signed a broad therapeutic development deal with Eli Lilly worth up to $2.6 billion, marking a new chapter for the Korean biotech.Previously known for shuttle technology to enable therapeutics to cross the blood-brain-barrier, ABL has neurology-focused partnerships with Sanofi and GSK. Now, the drugmaker is widening the scope of its bispecific antibody platform, dubbed Grabody, and the validation from its deal with Lilly — as well as the US pharma's cash — will help it explore more disease areas. The tie-up with Lilly also follows ABL's push into antibody-drug conjugates (ADCs) via its backing of US biotech NEOK Bio, which emerged from stealth earlier this month with $75-million in funding.Expansion underwayIn addition to its Grabody-B shuttle technology, ABL's platform also includes Grabody-T for modular bispecific T-cell engager development and Grabody-I for bispecifics that modulate the immune system, both geared towards oncology.Under the multi-programme deal, ABL will receive $40 million upfront to develop multiple therapeutics across modalities and disease areas with Lilly. The Korean firm is eligible for up to $2.56 billion in development, regulatory and commercial milestones, plus tiered royalties. Lilly also took a stake in the company, buying 175,079 common shares at KRW 125,900 per share for a total investment of KRW 22 billion ($15 million).With the funds, ABL plans to expand the reach of its Grabody technology into obesity and muscle diseases.